Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Total Current Liabilities (2017 - 2025)

Sutro Biopharma's Total Current Liabilities history spans 9 years, with the latest figure at $71.9 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 45.24% year-over-year to $71.9 million; the TTM value through Sep 2025 reached $71.9 million, down 45.24%, while the annual FY2024 figure was $131.9 million, 40.69% up from the prior year.
  • Total Current Liabilities for Q3 2025 was $71.9 million at Sutro Biopharma, down from $74.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $133.0 million in Q1 2025 and bottomed at $22.7 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $67.1 million (2023), against an average of $72.6 million.
  • The largest annual shift saw Total Current Liabilities surged 93.65% in 2024 before it tumbled 45.24% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $41.7 million in 2021, then soared by 59.45% to $66.5 million in 2022, then skyrocketed by 40.87% to $93.7 million in 2023, then surged by 40.69% to $131.9 million in 2024, then tumbled by 45.49% to $71.9 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Total Current Liabilities are $71.9 million (Q3 2025), $74.2 million (Q2 2025), and $133.0 million (Q1 2025).